By Sherri Oslick --
About Court Report: Each week we will report briefly on recently filed biotech and pharma cases.
Pfizer Inc. et al. v. Watson Pharmaceuticals Inc. et al.
1:11-cv-00914; filed October 6, 2011 in the District Court of Delaware
• Plaintiffs: Pfizer Inc.; Alpharma Pharmaceuticals LLC; King Pharmaceuticals Inc.
• Defendants: Watson Pharmaceuticals Inc.; Watson Laboratories Inc.; Watson Pharma Inc.; Watson Laboratories Inc. - Florida
Infringement of U.S. Patent Nos. 7,682,633 ("Pharmaceutical Composition," issued March 23, 2010), 7,682,634 ("Pharmaceutical Compositions," issued March 23, 2010), and 7,815,934 ("Sequestering Subunit and Related Compositions and Methods," issued October 19, 2010) following a Paragraph IV certification as part of Watson's filing of an ANDA to manufacture a generic version of Pfizer subsidiary King Pharmaceutical's EMBEDA® (morphine sulfate and naltrexone hydrochloride extended release capsules, used in the management of moderate to severe pain). View the complaint here.
Eisai Inc. v. Banner Pharmacaps Inc.
1:11-cv-00901; filed October 4, 2011 in the District Court of Delaware
Infringement of U.S. Patent Nos. 5,780,676 ("Compounds Having Selective Activity for Retinoid X Receptors, and Means for Modulation of Processes Mediated by Retinoid X Receptors," issued July 14, 1998) and 5,962,731 (same title, issued October 5, 1999) following a Paragraph IV certification as part of Banner's filing of an ANDA to manufacture a generic version of Eisai's Targretin® (bexarotene, used to treat cutaneous T-cell lymphoma). View the complaint here.
Cellectis S.A. v. Precision Biosciences Inc.
1:11-cv-00890; filed September 30, 2011 in the District Court of Delaware
Declaratory judgment of invalidity and non-infringement of U.S. Patent No. 8,021,867 ("Rationally Designed Meganucleases with Altered Sequence Specificity and DNA-Binding Affinity," issued September 20, 2011) based on Cellectis' manufacture and sale of its engineered I-Crel meganucleases. View the complaint here.
Comments